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Alterations in the levels of molecules which interact with the extracellular matrix, such as integrins,
are associated with invasion of oral squamous cell carcinomas (OSCC). The molecular mechanisms
underlyingdysregulationof integrin expression inOSCC, however, remainunclear.Here,we showthat
microRNA-124, a small non-coding RNA down-regulated in OSCC, is able to downregulate expression
of integrin beta-1 (ITGB1) by interacting with its 30 untranslated region. Over-expression of miR-124
attenuates endogenous ITGB1 expression and reduces the adherence and motility of OSCC cells, sug-
gesting disruption ofmiR-124-mediated repression of ITGB1may be a key factor in OSCC progression.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Recently, it has been demonstrated that the expression of someOral squamous cell carcinomas (OSCC) account for over 40% of
head and neck malignancies and are the sixth most common can-
cer worldwide. OSCC have a particularly poor prognosis due to
their invasive nature, and despite advances in treatment and diag-
nostics, the ﬁve-year survival rates remain at less than 50% and
have not improved in the last three decades [1]. Early detection
and treatment of OSCC, before the tumour begins to invade under-
lying structures and metastasise, improves prognosis dramatically.
OSCC typically spreads by invading through the underlying extra-
cellular matrix (ECM) into the lymphatic system, a process associ-
ated with changes in the levels of molecules which maintain and
modify the ECM such as matrix metalloproteinases (MMPs) and
integrins [2]. Integrins are a family of heterodimeric cell surface
proteins, composed of a- and b-subunits, which interact with com-
ponents of the ECM such as ﬁbronectin. These interactions and
associated signalling mediate the growth, differentiation and inva-
sive capacity of oral epithelial cells [3]. Changes in the expression
levels of a variety of integrins have been identiﬁed in OSCC and
are thought to play a critical role in its progression [4]. The molec-
ular mechanisms underlying the dysregulation of the expression of
integrins in OSCC, however, remain to be fully elucidated.chemical Societies. Published by E
ma; ITGB1, integrin beta-1;
; ECM, extracellular matrix;
lofacial Pathology, School of
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Lambert).ECM components may be regulated by speciﬁc microRNAs (miR-
NAs) [5]. miRNAs are short, naturally occurring non-coding RNAs
which regulate the expression of target genes by binding to speciﬁc
sequences in the 30 untranslated region (30UTR) of their transcripts
[6]. The discovery of miRNAs has unveiled a new complexity in the
regulation of gene expression and it is becoming increasingly
apparent that miRNAs have a critical role in a wide variety of bio-
logical processes [7]. Widespread dysregulation of the expression
of miRNAs has been identiﬁed in a number of malignancies [8],
including oral cancer [9], suggesting that miRNA-mediated regula-
tion of gene expression may be an important factor in the aetiology
of malignancy. In this study we sought to identify regulatory miR-
NAs potentially targeting integrin beta-1 (ITGB1), a widely ex-
pressed integrin with critical roles in mediating cell:ECM
interactions, and to examine the pathological signiﬁcance of any
such interaction in OSCC.2. Materials and methods
2.1. Bioinformatics
In silico prediction of miRNA binding sites within the ITGB1
30UTR was performed using TargetScan (www.targetscan.org).2.2. Cell culture and mi/siRNA transfection
SCC4 and H357 cells (OSCC-derived cell lines) and Huh7 cells
(hepatocellular carcinoma-derived) were routinely cultured inlsevier B.V. All rights reserved.
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at approximately 60% conﬂuence using Oligofectamine reagent
(Invitrogen) with pre-miR-124, siRNA targeted to ITGB1 (Applied
Biosystems) or negative control siRNA (ﬁnal concentration
50 nM) in Opti-MEM medium (Invitrogen). Cells were incubated
for 24 h prior to harvesting.
2.3. Luciferase reporter assay
The ITGB1 30UTR was ampliﬁed from human cDNA using ITGB1
forward (50 TTT TGA GCT CGT ACT GCC CGT GCA AAT CCC ACA A)
and reverse (50 TTT TAC GCG TTG CTT TTC CTC AAC TTC TTT AA)
primers containing SacI and MluI restriction sites, respectively.
The PCR fragment was cloned into pMIR-REPORT (Ambion). Huh7
cells were co-transfected using Lipofectamine 2000 reagent (Invit-
rogen) with 500 ng of the 30UTR-luciferase reporter vector, 100 ng
of pRL-TK Renilla luciferase control vector (Promega) and pre-miR-
NA or negative control siRNA (ﬁnal concentration 18.75 nM). After
24 h incubation, Fireﬂy and Renilla luciferase activities were mea-
sured using the dual-luciferase assay kit (Promega), according to
the manufacturer’s instructions.
2.4. Site directed mutagnesis
Putative miR-124 binding sites were abolished using the PCR-
based QuikChange II XL site-directed mutagenesis kit (Stratagene).
The following primers were utilised to replace the putative seed
sequences with the complementary bases; mutagenic bases are
highlighted in bold: ITGB1mutate124(A)forward 50 CAG CTA AGG
TCA CAT TCA CGG AAT TTG ACC TTT TCT TCC, ITGB1muta-
te124(A)reverse 50 GGA AGA AAA GGT CAA ATT CCG TGA ATG
TGA CCT TAG CTG, ITGB1mutate124(B)forward 50 CAC ATT CTT
GTT TTA ACA CGG AAT AGT TTT AAC AGT TC, ITGB1mutate124(B)-
reverse 50 GAA CTG TTA AAA CTA TTC CGT GTT AAA ACA AGA ATG
TG.
2.5. RNA isolation and quantitative real-time PCR
Total RNA was isolated from SCC4 cells using the RNeasy mini
kit (Qiagen) and quantiﬁed using a NanoDrop spectrophotometer.
The TaqMan MicroRNA Reverse Transcription kit (Applied Biosys-
tems) was used for synthesis of cDNA from 10 ng total RNA. cDNA
was subsequently analysed by Taqman qPCR using the miR-124 as-
say (Applied Biosystems) or by SYBR green qPCR using primers for
ITGB1 [10] and U6 [11]. All values were normalised to U6 expres-
sion levels.
2.6. Protein extraction and western blot
Cells were washed twice with Dulbecco’s phosphate buffered
saline and protein was extracted using triple detergent lysis Buffer
(0.1 M Tris–HCl pH 7.4, 0.15 M NaCl, 1% (v/v) Triton X-100, 0.1% (v/
v) Nonidet P-40 and 0.1% (w/v) SDS) containing Complete Mini
Protease Inhibitor Cocktail (Roche). Protein concentrationwasmea-
sured using BCA Protein Assay Kit (Thermo). Total protein extracts
(50 lg) were separated by 8% (v/v) SDS–PAGE and transferred to
nitrocellulose membrane. Following blocking of non-speciﬁc pro-
tein binding, membranes were incubated with antibodies directed
to ITGB1 (1:1000, Millipore), GAP-DH (1:2000, Abcam) or b-actin
(1:10,000, Sigma). Horseradish peroxidase-conjugated secondary
antibodies (Sigma)were diluted 1:5000. All antibodies were diluted
in 5% (w/v) dried milk in Tris-buffered saline containing 0.05% (v/v)
Tween 20. Immunoreactive proteins were visualised by enhanced
chemiluminescence (ECL, Pierce). Densitometry was performed
using Adobe Photoshop.2.7. Cell adhesion assay
Adhesion assays were carried out in 96-well plates. Wells were
coated with ﬁbronectin (10 lg/ml) at 4 C for 18 h and washed
twice with PBS. Transfected cells were trypsinised, counted using
a haemocytometer and resuspended in serum-free DMEM
(2  105/ml). 100 ll cell suspension was added to each well and
cells were allowed to adhere for 1 h at 37 C. Wells were washed
twice with PBS to remove unadhered cells and 100 ll serum-free
DMEM was added to each well. Adherent cells were quantiﬁed
using MTS reagent (Promega) and measuring absorbance at
490 nm.
2.8. Cell migration assay
SCC4 migration was measured using Transwell Chambers
(Corning). Transfected cells were trypsinised and resuspended in
DMEM containing 0.1% (w/v) BSA at 5  105 cells/ml and 200 ll
cell suspension was added to the migration chamber. 750 ll
DMEM containing 20% (v/v) FBS was added to the well. After 4 h
incubation, cells were swabbed away from the inside of the migra-
tion chamber and cells adhering to the underside of the chamber
were ﬁxed for 10 min in 100% (v/v) methanol. Cells were then
stained with 0.1% (w/v) crystal violet and counted by light
microscopy.
2.9. Cell invasion assay
SCC4 invasion was assayed using growth-factor depleted Matri-
gel invasion chambers (BD Biosciences). Matrigel chambers were
re-hydrated for 1 h in 500 ll serum-free DMEM, after which the
medium was removed from the insert and 750 ll DMEM contain-
ing 20% (v/v) FBS was added to the well. Transfected cells were
trypsinised and resuspended in DMEM containing 0.1% (w/v) BSA
at 4  105 cells/ml and 500 ll cell suspension was added to the
invasion chamber. After 18 h incubation, cells were swabbed away
from the inside of the invasion chamber and cells adhering to the
underside of the chamber were ﬁxed for 10 min in 100% (v/v)
methanol. Cells were then stained with 0.1% (w/v) crystal violet
and counted by light microscopy.
3. Results
3.1. miR-124 targets ITGB1
Using a bioinformatics approach, miR-124, a miRNA previously
shown to be downregulated in an animal model of oral cancer [12],
was predicted to target the ITGB1 30UTR via two separate binding
sites (Fig. 1A). The two putative binding sites were identiﬁed at re-
mote locations within the UTR, separated by about 900 bp. To con-
ﬁrm that miR-124 was able to interact with the putative binding
sites, the entire 30UTR was cloned into the pMIR-REPORT luciferase
reporter vector. Huh7 cells (a cell line in which we have optimised
reporter assays to determine miRNA function) were co-transfected
with the resulting construct and pre-miR-124 or a negative control
oligonucleotide. Luciferase reporter assays showed signiﬁcantly
lower expression (>50% reduction) of Fireﬂy luciferase in the pres-
ence of miR-124, compared to the negative control scramble siRNA
(Fig. 1B). Having established that miR-124 is able to directly inhibit
ITGB1, we next sought to identify the sites of interaction in the
ITGB1 30UTR. Mutation of the ﬁrst predicted seed sequence alone
to the complementary sequence (235–241; ITGB1D124A) had no
effect on miR-124-mediated reduction; mutation of the second
predicted site of interaction alone (1094–1100; ITGB1D124B) sig-
niﬁcantly reduced inhibition of ITGB1. Mutation of both predicted
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Fig. 1. miR-124 targets the ITGB1 30UTR. (A) In Silico analysis, performed using TargetScan, identiﬁed two putative miR-124 binding sites at positions 235–241 base pairs and
1094–1100base pairs of the ITGB130UTR. (B) The ITGB130UTRwas cloned into pMIR-REPORT luciferase reporter vector (WT) and the predictedmiR-124 binding sitesmutated to
the complementary sequence by site directed mutagenesis individually (DmiR-124A andDmiR-124B, as indicated in B), or in combination (DmiR-124A/B), and co-transfected
with either miR-124 or a control, scrambled oligonucleotide into Huh7 cells. Activities of Fireﬂy and Renilla (endogenous control) were assayed 24 h post transfection. Data
presented represents the ratio of Fireﬂy/Renilla activities normalised to empty vector ± S.E.M. (n = 6, * = P < 0.01 by Mann–Whitney U Test, ns = not signiﬁcant).
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tory effect of miR-124 (Fig. 1B).
3.2. miR-124 causes degradation of the ITGB1 transcript
and abrogation of ITGB1 protein
Having determined that miR-124 is able to interact directly with
the ITGB1 30UTR we next sought to investigate its effect on ITGB1
gene expression.We therefore carried out immunoblotting for ITGB1
onOSCC cells transfectedwithpre-miR-124or a control oligonucleo-
tide. Overexpression ofmiR-124 resulted in a signiﬁcant reduction in
ITGB1 protein levels compared to control cells (Fig. 2A). MiRNA are
thought to suppress the expression of target genes by either inhibit-
ing translation (without reducing transcript levels) or promoting
degradation of their transcripts. To ascertain the mechanism by
which miR-124 reduces ITGB1 expression we employed real-time
PCR(qPCR) toquantify transcript levels inSCC4cells transfectedwith
pre-miR-124. Analysis revealed signiﬁcant reductionof ITGB1mRNA
transcript (>70%) in cells transfectedwith pre-miR-124, compared to
mock transfectedcells or cells transfectedwithacontrol oligonucleo-
tide (Fig. 2B). Comprehensive qPCR analysis of other integrin sub-
units failed to show any signiﬁcant changes in expression upon
miR-124 over-expression (data not shown).3.3. miR-124 inhibits OSCC motility
We next examined the ability of miR-124 to inﬂuence the
migration and invasion of OSCC cells in culture. SCC4 cells were
utilised for these studies as they have previously been shown to
harbour a gain-of-function mutation in ITGB1 which renders it
constitutively active [13]. This relieves it from the requirement of
heterodimerization for activation, potentially amplifying any phe-
notypic sequelae of modulating its expression. Over-expression of
miR-124 in SCC4 cells caused a signiﬁcant decrease in migration
(Fig. 3A) and invasion through Matrigel (Fig. 3B) compared to mock
transfected cells or cells transfected with a scrambled control oli-
gonucleotide. The decrease in migration mirrored the effect of
abrogating ITGB1 expression using siRNA (Fig. 3C), suggesting the
observed phenotype is due, at least in part, to repression of ITGB1.
3.4. miR-124 reduces adherence of H357, but not SCC4, to ﬁbronectin
Having established the ability of miR-124 to abrogate the motil-
ity of OSCC cells, we next examined its ability to inﬂuence cell:ECM
interactions. Surprisingly, miR-124-mediated inhibition of ITGB1
had little effect on the ability of SCC4 cells to adhere to ﬁbronectin,
a major component of the ECM and known ITGB1 ligand (Fig. 4A).
00.5
1
1.5
ITGB1
R
el
at
iv
e 
IT
G
B1
 p
ro
te
in
 a
bu
nd
an
ce
mo
ck
miR
-12
4
con
trol
A
0
0.5
1
1.5
2
mo
ck
miR
-12
4
con
trol
R
el
at
iv
e 
IT
G
B1
 tr
an
sc
rip
t a
bu
nd
an
ce
B
* *
* *
β-actin
Fig. 2. miR-124 downregulates ITGB1 protein and mRNA expression in OSCC in culture. (A) SCC4 cells were transfected with precursors to miR-124 and a control
oligonucleotide not predicted to bind the ITGB1 30UTR. Cell lysates were prepared after 24 h and subjected to immunoblotting for ITGB1 or b-actin. The levels of ITGB1 were
determined and normalised to b-actin by densitometry. (B) SCC4 cells were transfected in the same manner, RNA isolated and the levels of ITGB1 and U6, as an internal
control, assessed by qPCR as described in Section 2. Data presented represent the mean ± S.E.M. of three independent experiments (*P < 0.05 by Student t-test).
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Fig. 3. miR-124 inhibits migration and invasion of OSCC cells. SCC4 cells were transfected with miR-124, siRNA targeting ITGB1 (si-ITGB1) or negative control scrambled
oligonucleotide. Cells were assayed for their ability to migrate across a permeable ﬁlter (A and C) and invade through Matrigel (B) 24 h post transfection, as described in
Section 2. Data presented represents the number of migrating or invading cells normalised to mock transfection ± S.E.M. (nP 8, * = P < 0.01 by Mann–Whitney U test).
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integrin b6 (ITGB6), compensating for the reduction in ITGB1.
ITGB6 is commonly over-expressed in OSCC [14] and has a high
afﬁnity for ﬁbronectin; we therefore examined the compensatorycontribution of ITGB6 to ﬁbronectin adhesion by utilising a differ-
ent OSCC cell line, H357, which does not express functional b6 [15].
Over-expression of miR-124 in H357 signiﬁcantly inhibited adhe-
sion to ﬁbronectin (Fig. 4B) and reduced ITGB1 expression
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Fig. 4. miR-124-mediated repression of ﬁbronectin binding is dependent on integrin expression proﬁle. SCC4 cells (A) or the ITGB6 deﬁcient H357 (B–D) were transfected
with miR-124, siRNA targeting ITGB1 (si-ITGB1) or negative control scrambled oligonucleotide. Cells were assayed for their ability to adhere to ﬁbronectin (A, B, and D) or
immunoblotted for ITGB1. (C) 24 h post transfection, as described in Section 2. Data presented represents the number of adherent cells normalised to mock transfection or
densitometrical analysis of immunoblots relative to GAP-DH ± S.E.M. (nP 3, * = P < 0.01 by Mann–Whitney U test).
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ulation of ITGB1. This was corroborated by the observation that
siRNA targeting ITGB1 also reduced adhesion of H357 cells to ﬁbro-
nectin to a similar degree (Fig. 4D).
4. Discussion
In order to gain insight into the molecular mechanisms involved
in pathogenesis of invasive OSCCs, we investigated the possibility
that molecules interacting with the ECM may be subject to
post-transcriptional regulation by miRNA. Aberrant expression of
miRNA is increasingly recognised to play an important role in the
promotion of carcinogenesis and metastasis. We ﬁrst employed a
bioinformatics approach to identify potential regulatory miRNAs
targeting members of the integrin family, a group of cell surface
proteins which modulate cell:ECM interactions. We identiﬁed evo-
lutionarily conserved binding motifs for miR-124 in the 30UTR of
one of the most widely expressed integrin subunits, ITGB1. ITGB1
is thought to play an important role in maintaining tissue homeo-
stasis by interacting with components of the ECM and directing
regulatory intracellular signalling cascades. Aberrant activation
and expression of ITGB1 has been detected in a variety of malig-
nancies, including oral cancer, and is implicated in the aetiology
of an invasive, metastatic phenotype [3]. A recent study demon-strated down-regulation of miR-124 in an animal model of oral
carcinogenesis [12], and silencing of miR-124 has been docu-
mented in other cancers [16,17]. We therefore sought to determine
whether miR-124 is able to suppress ITGB1 in OSCC cells in culture,
and assess the effect of miR-124 modulation on cell:ECM interac-
tion and motility.
Direct interaction of miR-124 with the 30UTR was demon-
strated using a luciferase reporter assay; cotransfection of miR-
124 with a reporter vector containing the ITGB1 30UTR signiﬁ-
cantly reduced luciferase expression in cancer cells. A previous
study identiﬁed a functional interaction between miR-124 and
ITGB1 in chicks [18], but this has not been analysed in humans
to date, and the precise sites of interaction have not been
mapped. The ITGB1 30UTR contains two conserved miR-124 bind-
ing motifs. Abolition of both of these sites rescued the expression
of luciferase in the presence of miR-124, conﬁrming the direct
interaction of miR-124 with one or both of these sites. Our data
suggests that both sites are required for miR-124-mediated
reduction of ITGB1, as deletion of each site individually had minor
or no effects. This suggests that co-operativity may exist between
the sites, possibly as a result of conformational changes occurring
upon miR-124 binding. This possibility has been suggested previ-
ously for other miRNAs; the underlying mechanisms, however, re-
main unclear [19].
192 S. Hunt et al. / FEBS Letters 585 (2011) 187–192Having established the ability of miR-124 to directly repress
ITGB1, we next demonstrated that over-expressing miR-124 re-
duces endogenous ITGB1 expression in OSCC cells which display
reduced miR-124. This reduction was the result of decreased ITGB1
transcript rather than due to inhibition of translation. The levels of
the transcripts for other integrin subunits analysed were not al-
tered, indicating speciﬁcity of the ITGB1-miR-124 interaction in
terms of integrin regulation. Although miRNA are known to sup-
press target gene expression by promoting transcript decay or by
blocking translation, the precise molecular mechanisms involved
remain controversial [20].
Over-expression of miR-124 signiﬁcantly inhibited migration of
the OSCC-derived cell line SCC4 cells and reduced their invasive
capacity; a similar effect on migration was observed using siRNA
targeting ITGB1, implicating ITGB1 depletion in the miR-124-in-
voked phenotype. Interestingly, the effect of miR-124-mediated
suppression of ITGB1 on adhesion to the ITGB1 ligand ﬁbronectin
appeared to be cell-type speciﬁc. miR-124 was able to inhibit the
adhesion of H357 cells (as was siRNA targeting ITGB1) but not
SCC4 cells; we postulate this difference may be due to the dispa-
rate integrin expression proﬁles of the two cell lines. While both
express high levels of ITGB1, only SCC4 express ITGB6, another
ﬁbronectin-binding integrin which may be able to compensate
for the reduction in ITGB1 invoked by miR-124 over-expression
(ITGB6 levels were not altered by miR-124 over-expression, data
not shown). We have previously shown that the invasion of
ITGB6-expressing OSCC cells can be inhibited by antibodies block-
ing ITGB1 alone, but in order to suppress adhesion both ITGB1 and
ITGB6 must be functionally blocked [15], in keeping with the ﬁnd-
ings reported here.
In silico analysis of predicted miR-124 targets reveals a number
of genes with potential roles in cell:ECM interactions and metasta-
sis; this is unsurprising as each miRNA is predicted to potentially
target hundreds of genes, and is in keeping with the emerging
hypothesis that speciﬁc miRNA may target speciﬁc cellular pro-
cesses rather than individual genes [21]. It is likely, therefore, that
the tumour-suppressive effect of miR-124 is not solely the result of
repression of ITGB1; this molecule, however, is known to contrib-
ute signiﬁcantly to cancer pathogenesis, and the effects of abrogat-
ing ITGB1 using siRNA closely mirrored those of over-expressing
miR-124. Furthermore, a recent study demonstrated that targeting
of ITGB1 by another miRNA, miR-183, was directly responsible for
reducing the invasion and migration of HeLa cells [10]. In addition,
we have previously shown that blocking ITGB1 function using spe-
ciﬁc antibodies reduces the migration and invasion of OSCC cells
in vitro [15]. We are currently investigating the ability of heterol-
ogously expressed ITGB1 to reverse the changes in OSCC cell
behaviour invoked by miR-124 over-expression.
In conclusion we have demonstrated, for the ﬁrst time, the abil-
ity of miR-124 to suppress OSCC invasion and migration by down-
regulating ITGB1 expression. These ﬁndings further contribute to
our understanding of integrin-mediated modulation of cell behav-
iour and may provide a platform from which novel therapies tar-
geting OSCC invasion can be developed. In addition, we are
currently evaluating the possibility that miR-124 may be useful
as a prognostic indicator in OSCC.Acknowledgements
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